Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALUE: Icosapent Ethyl Mechanism in Dyslipidemia
NCT03885661Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Jan 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omega-3-acid triglycerides in hypertriglyceridemia (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Change in VLDL-apoB100 Production Rate at 13 weeks. Started Jan 2016; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03885661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03885661.